Study About Efficacy and Safety to Treat Multi-System-Atrophy
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
Study Hypothesis:
- Does a treatment with Minocycline of 2 x daily 2 x 50 mg effect the progression of clinical
symptoms and diagnosis in patients with MSA?
Background and Rationale:
- The Parkinson-Syndrome which is characterised by the clinical triad akinesis, rigor and
passive tremor, is caused by Parkinson's disease (PD) in about 70 % of the cases (Oertel
et al., 2003). However, beside the Parkinson's disease there are several, to some extent
rare, so-called atypical Parkinson's syndromes. The two most frequent of these atypical
Parkinson-Syndromes are the
- Multi-System-Atrophy (MSA) and the Progressive Supranuclear Palsy (PSP). Due to the
often much varying courses and since they are not well known, these diseases are
frequently diagnosed late or not diagnosed at all. Nevertheless, an early diagnosis is
substantial for further treatment, since the prognosis and therapy of atypical Parkinson
Syndromes differ essentially from those of PD. Whereas the neuronal death of cells in PD
is restricted essentially to the Substantia nigra, a dominant destruction of neurons in
brain stem, Cerebellum and Striatum additionally happens in cases of MSA and PSP.
- Up to now no adequate treatment strategies are at disposal. Initially the giving of
L-Dopa can lead to an improvement for < 10% of the patients only.
- Minocycline is an antibiotic belonging to the group of the Tetracyclines.
- Recently, it could be demonstrated that Minocycline has a neuroprotective impact besides
the anti-inflammatory impact.
Phase:
Phase 3
Details
Lead Sponsor:
German Parkinson Study Group (GPS)
Collaborators:
Competence Network on Parkinson's Disease European MSA-Study Group Federal Institute of Education and Sience